McGuire Investment Group LLC Has $20.01 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

McGuire Investment Group LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,353 shares of the medical research company’s stock after buying an additional 556 shares during the quarter. Thermo Fisher Scientific comprises about 2.8% of McGuire Investment Group LLC’s holdings, making the stock its 11th largest position. McGuire Investment Group LLC’s holdings in Thermo Fisher Scientific were worth $20,013,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of TMO. Brookstone Capital Management boosted its stake in Thermo Fisher Scientific by 252.4% during the first quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock worth $2,550,000 after acquiring an additional 3,142 shares in the last quarter. Leo Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $1,117,000. BDF Gestion acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $6,368,000. Aviance Capital Partners LLC boosted its holdings in Thermo Fisher Scientific by 20.9% in the first quarter. Aviance Capital Partners LLC now owns 13,043 shares of the medical research company’s stock worth $7,581,000 after acquiring an additional 2,251 shares in the last quarter. Finally, Lord Abbett & CO. LLC increased its holdings in shares of Thermo Fisher Scientific by 1.9% during the first quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock valued at $45,478,000 after acquiring an additional 1,480 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on TMO. Stephens began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target for the company. Wells Fargo & Company assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price objective for the company. Evercore ISI lifted their price target on Thermo Fisher Scientific from $605.00 to $630.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird increased their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Finally, JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $653.72.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the transaction, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the transaction, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock worth $14,094,292 in the last 90 days. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

TMO stock traded up $3.13 during midday trading on Friday, reaching $596.92. The company had a trading volume of 2,138,162 shares, compared to its average volume of 1,154,217. The firm has a 50-day moving average price of $607.73 and a 200-day moving average price of $583.44. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The company has a market capitalization of $228.02 billion, a P/E ratio of 37.03, a P/E/G ratio of 3.80 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.15 earnings per share. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.